Pentadeca Arginate

Last Updated: July 2026

Pentadeca Arginate (PDA) is not a new molecule — it is the arginine-salt form of BPC-157, carrying the identical 15-amino-acid sequence (GEPPPGKPADDAGLV, "pentadeca" = 15). The only difference from standard BPC-157 is the counterion: an arginine salt in place of the more common acetate. The peptide itself is unchanged. It is researched, like BPC-157, for tissue repair and cytoprotection, is not approved by the FDA or any regulator, and is supplied strictly for research use only.

What is Pentadeca Arginate, and how is it different from BPC-157?

PDA and BPC-157 are the same peptide sequence — the "arginate" refers only to the salt counterion paired with the molecule, not a change to the amino acids. Research-grade peptides are supplied as salts (a counterion improves stability or handling); BPC-157 is conventionally an acetate salt, and PDA is the same peptide as an arginine salt. Vendor materials claim the arginate form is dramatically more stable (e.g. "1,000× more stable" at stomach pH), but that claim has not been published in any peer-reviewed journal and appears to originate from compounding-vendor documentation, not independent testing. Treat the stability advantage as a marketing claim, not an established fact.

What does the research on PDA actually show?

There is no peer-reviewed study of pentadeca arginate as a distinct molecule — the entire evidence base belongs to BPC-157, and even that is almost entirely preclinical. BPC-157 has extensive rodent data for tendon, muscle, ligament, gut, and vascular healing (angiogenesis, collagen synthesis, anti-inflammatory effects), but a 2025 systematic review identified only a single small human study of BPC-157 (a 12-patient retrospective case series), and reviews note there are very few studies on any modified BPC-157 analogue. Evidence level: Preclinical (BPC-157, rodent); none specific to PDA. For full mechanism and evidence, see the BPC-157 profile.

Is PDA more effective than regular BPC-157?

No study has demonstrated that the arginate salt outperforms the acetate form in any biological outcome. Because the active peptide is identical, any difference would come only from pharmacokinetics (absorption/stability), and that has not been shown in independent, peer-reviewed research. Marketing that presents PDA as a clinically superior "next-generation BPC-157" is running ahead of the evidence.

What are the known side effects and safety concerns?

Because PDA is molecularly BPC-157, its safety picture is BPC-157's — a favorable preclinical profile with few reported adverse effects, but no comprehensive human safety data. BPC-157 was temporarily placed on the WADA prohibited list in 2022 (it is not currently listed). There are no controlled human safety trials establishing a safe dose, and the arginate counterion has not been separately safety-characterized. Evidence level: Preclinical. See the legal status by country guide.

Why does vendor verification matter for PDA?

Because "PDA" and "BPC-157" are the same peptide, a key verification question is simply whether a vial contains the correct pentadecapeptide at the labeled amount — and whether "arginate" branding is being used to justify a price premium over ordinary BPC-157. Independent HPLC (purity) and mass-spec (identity, expected free-peptide MW ~1419.6 Da) are the objective checks. Learn how to read them in the how-to-test hub and the COA red-flags guide.

How does Peptigrity verify PDA vendors?

Peptigrity buys PDA anonymously at standard pricing, submits it to independent ISO-accredited labs for HPLC and mass-spectrometry, and publishes the unedited certificate of analysis. The table above shows the cross-shop dataset. Our trust score weights independent lab purity and community reviews equally (50/50) — see how we calculate trust scores.

Educational information only; not medical advice. Pentadeca Arginate / BPC-157 is not approved by the FDA or any regulator for human use. Consult a qualified healthcare provider before using any research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend products or vendors.